Company / Interest Expense
Axsome Therapeutics, Inc. Interest Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
-$15.9M
FY2025
5-year range
-$21.6M / -$9.7M
FY2022-FY2025
Trend
+26.2%
vs FY2024
Sector context
#43 of 44
Health Care
What the data says
Among 44 Health Care companies, Axsome Therapeutics, Inc. is in the top 2% for interest expense. Interest Expense returned to growth in FY2025 after 2 years of decline, reaching -$16M.
Based on SEC 10-K filings.
-$16M in FY2025.
Increased from -$20M to -$16M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 44This company -$15.9M Sector average $291.0M
▼
-105.5% below sector average
Key checks
Key Insights
- In FY2025, interest expense increased 26.2% year-over-year.
- Ranks #43 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$15.9M | +26.2% |
| FY2024 | -$21.6M | -7.7% |
| FY2023 | -$20.0M | -107.4% |
| FY2022 | -$9.7M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026